Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Current Assets (2021 - 2025)

Kezar Life Sciences' Current Assets history spans 4 years, with the latest figure at $156.4 million for Q3 2024.

  • For Q3 2024, Current Assets fell 32.16% year-over-year to $156.4 million; the TTM value through Sep 2024 reached $156.4 million, down 32.16%, while the annual FY2023 figure was $207.0 million, 27.57% down from the prior year.
  • Current Assets for Q3 2024 was $156.4 million at Kezar Life Sciences, down from $167.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $311.3 million in Q2 2022 and bottomed at $124.8 million in Q3 2021.
  • The 4-year median for Current Assets is $211.7 million (2021), against an average of $214.2 million.
  • The largest annual shift saw Current Assets skyrocketed 139.62% in 2022 before it crashed 32.16% in 2024.
  • A 4-year view of Current Assets shows it stood at $211.7 million in 2021, then skyrocketed by 34.99% to $285.7 million in 2022, then decreased by 27.57% to $207.0 million in 2023, then decreased by 24.44% to $156.4 million in 2024.
  • Per Business Quant, the three most recent readings for KZR's Current Assets are $156.4 million (Q3 2024), $167.6 million (Q2 2024), and $185.6 million (Q1 2024).